Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic

The discovery of antifibrotic agents have resulted in advances in the therapeutic management of idiopathic pulmonary fibrosis (IPF). Currently, nintedanib and pirfenidone have become the basis of IPF therapy based on the results of large randomized clinical trials showing their safety and efficacy i...

Full description

Bibliographic Details
Main Authors: José M. Serra López-Matencio, Manuel Gómez, Esther F. Vicente-Rabaneda, Miguel A. González-Gay, Julio Ancochea, Santos Castañeda
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Pharmaceuticals
Subjects:
antifibrotic agents
COVID-19
interstitial lung disease
IPF
progressive fibrosing ILD
UIP
Online Access:https://www.mdpi.com/1424-8247/14/8/819

Similar Items

Similar Items